Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19.
Open accessThe DOI matches its Crossref record; 82 of the 86 references it cites were found in a registry or an index.
Abstract
Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials. Areas of Uncertainty: The majority of trialed agents have failed to provide reproducible, definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms with trial results reporting significant outcome benefits. Given some have not passed peer review, several expert groups including Unitaid/World Health Organization have undertaken a systematic global effort to contact all active trial investigators to rapidly gather the data needed to grade and perform meta-analyses. Data Sources: Data were sourced from published peer-reviewed studies, manuscripts posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of regions with ivermectin distribution campaigns. Therapeutic Advances: A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large “natural experiments” occurred in regions that initiated “ivermectin distribution” campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns. Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From late 2020 onwards, multiple groups produced meta-analyses that reported that ivermectin had a significant effect on survival, hospitalizations, clinical recovery, and viral clearance [2, 3].”
From Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before these inconsistencies were identified, the Elgazzar and Raad studies had been included in multiple meta-analyses, which suggested significant benefits for ivermectin in the treatment of COVID-19 [2, 3].”
From Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Elgazzar, A., Eltaweel, A., Youssef, S. A., Hany, B., Hafez, M., & Moussa, H. (2020) · doi:10.21203/rs.3.rs-100956/v3 · Cited by 17
RetractedDexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
How and why patients made Long Covid
Callard, F., & Perego, E. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.113426 · Cited by 924
Gardon, J., Gardon-Wendel, N., Demanga-Ngangue, Kamgno, J., Chippaux, J.-P., & Boussinesq, M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11094-1 · Cited by 745
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6820 · Cited by 734
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
Research works printed but not linked: 1
- Prophylaxis, 2020, Covid-19 in healthcare agents by intensive treatment with ivermectin and iota-carrageenan (Ivercar-Tuc), ClinicalTrials.gov, NCT04701710
Cited by
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
“We searched the reference list of included studies, and of two other 2021 literature reviews on ivermectin, 9 as well as the recent WHO report, which included analyses of ivermectin.”
BackgroundMethodIvermectin for preventing and treating COVID-19
Popp, M., Stegemann, M., Metzendorf, M.-I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub2 · Cited by 167
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S.-S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.704205 · Cited by 160
“Another anti-parasitic drug, ivermectin was tried for the treatment of COVID-19 patients since it showed anti-viral properties (Heidary and Gharebaghi, 2020; Kory et al., 2021).”
BackgroundCOVID ‐19: immunopathology, pathophysiological mechanisms, and treatment options
van Eijk, L. E., Binkhorst, M., Bourgonje, A. R., Offringa, A. K., Mulder, D. J., Bos, E. M., Kolundžić, N., Abdulle, A. E., van der Voort, P. H. J., Rikkert, M. G. M. O., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5642 · Cited by 172
Metadata
- Authors
- Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E.
- Affiliations
- Front-Line Covid-19 Critical Care Alliance, Madison, WI;
- University of Tennessee Health Science Center (US)
- University of Texas Health Science Center, Critical Care Service, Houston, TX;
- Department of Medicine, Hackensack School of Medicine, Seton Hall, NJ; and
- Eastern Virginia Medical School (US)
- Corresponding author
- Kory, Pierre
- Venue
- American Journal of Therapeutics
- Published
- 2021-04-22
- Volume
- 28
- Issue
- 3
- Pages
- e299-e318
- ISSN
- 1075-2765 (ISSN-L)
- PMC
- PMC8088823
- OpenAlex
- W3158596488
- Cited by
- 203
- References
- 86
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 21 · 2023: 59 · 2022: 56 · 2021: 54
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2022-02-07)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- ivermectin, COVID-19 pandemic, drug repurposing, prophylaxis, antiviral therapy, mortality reduction, natural experiment, SARS-CoV-2 transmission, viral clearance
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Antiparasitic Agents, Humans, Ivermectin, Treatment Outcome, Disease Transmission, Infectious
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. https://app.cochat.ai/papers/10.1097/mjt.0000000000001377
- The paper
- Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021). Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.